- Home
- DHIL vs HQL Comparison
DHIL vs HQL Comparison
Compare DHIL & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHIL
- HQL
- Stock Information
- Founded
- DHIL 1990
- HQL 1992
- Country
- DHIL United States
- HQL United States
- Employees
- DHIL N/A
- HQL N/A
- Industry
- DHIL Investment Managers
- HQL Investment Managers
- Sector
- DHIL Finance
- HQL Finance
- Exchange
- DHIL Nasdaq
- HQL Nasdaq
- Market Cap
- DHIL 392.1M
- HQL 369.6M
- IPO Year
- DHIL 1995
- HQL N/A
- Fundamental
- Price
- DHIL $133.40
- HQL $13.14
- Analyst Decision
- DHIL
- HQL
- Analyst Count
- DHIL 0
- HQL 0
- Target Price
- DHIL N/A
- HQL N/A
- AVG Volume (30 Days)
- DHIL 33.9K
- HQL 120.9K
- Earning Date
- DHIL 07-29-2025
- HQL 01-01-0001
- Dividend Yield
- DHIL 4.50%
- HQL 11.56%
- EPS Growth
- DHIL 21.42
- HQL N/A
- EPS
- DHIL 17.58
- HQL 0.79
- Revenue
- DHIL $151,281,009.00
- HQL N/A
- Revenue This Year
- DHIL N/A
- HQL N/A
- Revenue Next Year
- DHIL N/A
- HQL N/A
- P/E Ratio
- DHIL $7.59
- HQL $17.08
- Revenue Growth
- DHIL 6.29
- HQL N/A
- 52 Week Low
- DHIL $122.32
- HQL $11.34
- 52 Week High
- DHIL $173.25
- HQL $14.37
- Technical
- Relative Strength Index (RSI)
- DHIL 27.54
- HQL 51.20
- Support Level
- DHIL $151.00
- HQL $13.25
- Resistance Level
- DHIL $152.03
- HQL $13.44
- Average True Range (ATR)
- DHIL 3.66
- HQL 0.24
- MACD
- DHIL -2.48
- HQL -0.03
- Stochastic Oscillator
- DHIL 4.60
- HQL 41.54
About DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.